# Roger A. Levy

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/roger-a-levy/

## Facts

| Field | Value |
| --- | --- |
| Citations | 11,798 |
| Field | Systemic Lupus Erythematosus Research |
| h-index | 46 |
| i10-index | 111 |
| Last Known Institution | Glaxosmithkline (Finland) |
| OpenAlex ID | https://openalex.org/A5074421005 |
| ORCID iD | 0000-0001-6393-6031 |
| Works | 280 |

## Researcher papers

- [Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial](https://scholariq.org/papers/efficacy-and-safety-of-belimumab-in-patients-with-active-systemic-lupus/)
- [Treat-to-target in systemic lupus erythematosus: recommendations from an international task force](https://scholariq.org/papers/treat-to-target-in-systemic-lupus-erythematosus-recommendations-from-an/)
- [Catastrophic Antiphospholipid Syndrome: Clinical and Laboratory Features of 50 Patients](https://scholariq.org/papers/catastrophic-antiphospholipid-syndrome-clinical-and-laboratory-features-of-50/)
- [Anti-inflammatory and immunosuppressive drugs and reproduction.](https://scholariq.org/papers/anti-inflammatory-and-immunosuppressive-drugs-and-reproduction/)
- [The 2023 <scp>ACR</scp>/<scp>EULAR</scp> Antiphospholipid Syndrome Classification Criteria](https://scholariq.org/papers/the-2023-scp-acr-scp-scp-eular-scp-antiphospholipid-syndrome-classification/)
- [2023 ACR/EULAR antiphospholipid syndrome classification criteria](https://scholariq.org/papers/2023-acr-eular-antiphospholipid-syndrome-classification-criteria/)
- [Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: A randomized, double‐blind, placebo‐controlled trial in asymptomatic antiphospholipid antibody–positive individuals](https://scholariq.org/papers/aspirin-for-primary-thrombosis-prevention-in-the-antiphospholipid-syndrome-a/)
- [Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study](https://scholariq.org/papers/hydroxychloroquine-hcq-in-lupus-pregnancy-double-blind-and-placebo-controlled/)
- [A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)](https://scholariq.org/papers/a-framework-for-remission-in-sle-consensus-findings-from-a-large-international/)
- [Celecoxib Versus Naproxen and Diclofenac in Osteoarthritis Patients: SUCCESS-I Study](https://scholariq.org/papers/celecoxib-versus-naproxen-and-diclofenac-in-osteoarthritis-patients-success-i/)
- [Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression](https://scholariq.org/papers/systemic-lupus-erythematosus-lupus-nephritis-and-end-stage-renal-disease-a/)
- [Real-World Immunosuppressant Treatment Patterns for Patients with Lupus Nephritis in the United States](https://scholariq.org/papers/real-world-immunosuppressant-treatment-patterns-for-patients-with-lupus/)

## Researcher topics

- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)
- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Systemic Sclerosis and Related Diseases](https://scholariq.org/topics/systemic-sclerosis-and-related-diseases/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)
- [Pregnancy and Medication Impact](https://scholariq.org/topics/pregnancy-and-medication-impact/)

## Researcher university

- [Glaxosmithkline (Finland)](https://scholariq.org/institutions/glaxosmithkline-finland/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.